Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden’s State Of The Union Will Mention Drug Prices, But Not Outline Any New Plans

Executive Summary

President’s address to Congress expected to urge action on the provisions in the stalled Build Back Better legislation as part of a call to address inflation – though whether the speech will include the “i-word” remains unclear. PhRMA emphasizes that drug prices are stable.

You may also be interested in...



Drug Price Increases Accelerate: ‘Political Opportunism’ In A Return To Business As Usual?

Advocates for drug pricing reform don’t have much in the way of price increases to complain about at the moment – but they argue that the price hikes they are seeing suggest a growing confidence among manufacturers that the threat of drug pricing reform is subsiding.

Biden vs. Pharma: ‘You Come For The King…’

The president’s state of the union address comes after a year of mostly disappointing efforts for the administration on COVID and drug pricing.

Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA

Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel